Thera-SAbDab

ERENUMAB

>   Structural Summary
TherapeuticErenumab
TargetCALCRL
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS
Light ChainQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL
100% seqID Fv Structure6umh [Fvs: HL], 6umi [Fvs: HL], 6umj [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedAmgen, Novartis
Conditions ApprovedMigraine
Conditions Activena
Conditions DiscontinuedHot flashes
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]